|  |  |
| --- | --- |
| Address | Corp. Office: Block-B, Plot # 183 (6th Floor), Ahmed Akbar Sobhan Road, Bashundhara R/A, Baridhara, Dhaka-1229, Factory & Registered Office: 729 College Road, Barisal Sadar, Barisal-8200; Tel: +88-04-3161028,Fax:+88-02-312174977, email:info@indo-banglapharma.com;  web: www.indo-banglapharma.com |
| Nature of Business | Manufacturing and selling of all kinds of medicine (excluding Antibiotic), medical preparations drugs & chemicals (Human Health). |
| Major Products | Medicine for Human Health (Excluding Antibiotic) |
| Market for the products | Local Market |
| BSEC’s Consent for IPO | February 19, 2018 |
| Issue Date of Prospectus | March 13, 2018 |
| Subscription Open | August 09, 2018 |
| Subscription Close | August 16, 2018 |
| Security Trading Code | IBP |
| Public Offer of Ordinary Shares | 20mn |
| Offer Price | Tk. 10 each (at par) |
| Authorized Capital | Tk. 1,000mn |
| Pre-IPO Paid-up Capital | Tk. 730.00mn |
| IPO Size | Tk. 200.00mn |
| Post IPO Paid-up Capital | Tk. 930.00mn |
| Min. size for IPO subscription (per lot) | 500 |
| Foreign Currency reqd. for NRB and Foreign Applicants (per Lot) | USD 60.43 or GBP 43.60 or EUR 49.26 |
| Use of IPO proceeds | |  |  | | --- | --- | | Particulars | Amount (BDT) | | Machineries | 124.72mn (62.36%) | | Construction & Other Civil Works | 58.58mn (29.29%) | | IPO Expenses | 16.70mn (08.35%) | | Total | 200.00mn (100%) | |
| NAV Per Share | Tk. 12.84 as on June 30, 2017 |
| Earning Per Share (EPS) | Tk. 1.21 (for the period ended June **30, 2017)** |
| Dividend History | Nil from the year 2014 |
| Issue Manager | AFC Capital Limited & EBL Investment Limited |
| Auditor | Mahfel Huq & Co. |